Vanguard Group Inc. Has $124.74 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Vanguard Group Inc. lifted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 14.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,949,564 shares of the company's stock after purchasing an additional 369,387 shares during the period. Vanguard Group Inc. owned 4.66% of Vera Therapeutics worth $124,737,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. SG Americas Securities LLC grew its position in Vera Therapeutics by 116.7% during the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock worth $857,000 after acquiring an additional 10,916 shares during the last quarter. Lord Abbett & CO. LLC grew its holdings in Vera Therapeutics by 41.1% during the 3rd quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock worth $18,830,000 after acquiring an additional 124,197 shares during the last quarter. Barclays PLC increased its position in Vera Therapeutics by 94.1% in the 3rd quarter. Barclays PLC now owns 85,395 shares of the company's stock valued at $3,774,000 after acquiring an additional 41,394 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Vera Therapeutics by 2.1% in the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company's stock worth $44,415,000 after acquiring an additional 20,223 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Vera Therapeutics during the fourth quarter worth approximately $2,948,000. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Stock Performance

NASDAQ:VERA traded up $0.62 during mid-day trading on Friday, hitting $22.43. The stock had a trading volume of 1,535,188 shares, compared to its average volume of 758,343. The company's 50 day simple moving average is $27.58 and its 200 day simple moving average is $37.21. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -8.59 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. On average, equities research analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analysts Set New Price Targets

VERA has been the topic of several research reports. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target on the stock. Wolfe Research assumed coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective for the company. Guggenheim lifted their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Finally, JPMorgan Chase & Co. reduced their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $64.67.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.